Head of Global Clinical Development in Neurology at EMD Serono discussed the findings of a phase 2 assessment of the company’s investigational BTK inhibitor evobrutinib in multiple sclerosis.
Fernando Dangond, MD, MBA
Advertisement
Articles by Fernando Dangond, MD, MBA
The Head of Global Clinical Development in Neurology at EMD Serono provided insight into the therapy's performance in phase IIb.
Advertisement
Latest Updated Articles
Fernando Dangond, MD, MBA: Phase 2 Data on Evobrutinib in MSPublished: June 5th 2020 | Updated:
Fernando Dangond, MD, MBA: Evobrutinib for Relapsing Multiple SclerosisPublished: October 12th 2018 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy
2
Understanding Ocrelizumab’s Impact on Advanced Progressive MS: Insights From Dr. Gavin Giovannoni
3
FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology
4
Trofinetide Leads to Real-World Improvements in Rett Syndrome Symptoms, LOTUS Study Finds
5
